Trials
3 active
3 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Prostate Cancer (3 trials), Metastatic Castration-Resistant Prostate Cancer (2 trials), Metastatic Hormone Sensitive Prostate Cancer (2 trials), Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer
- Main trialPhase 2
- “Hormone therapy, or androgen deprivation therapy (ADT) is a standard way to treat prostate cancer. It works by reducing the amount of the main male sex hormone, testosterone in the body. Androgen receptor pathway inhibitors (ARPIs) are another type of hormone therapy. They either slow down how much testosterone is made or block testosterone from reaching the prostate cancer cells. Abiraterone acetate (AA) is an ARPI that is used to treat advanced prostate cancer. This type of treatment is usually given as a tablet with a steroid called prednisone/prednisolone to manage any medical problems…”In the company’s words, NCT07005154 on ClinicalTrials.gov
- Other names
- ASP5541
Other drugs for Prostate Cancer
- ApalutamideJohnson & Johnson (Janssen) · Phase 3
- 64Cu-SAR-bisPSMAClarity Pharmaceuticals Ltd · Phase 3
- Abiraterone acetateJohnson & Johnson (Janssen) · Phase 3
- 68Ga-PSMA-11Telix Pharmaceuticals (Innovations) Pty Limited · Phase 3
- EnzalutamidePfizer · Astellas · Phase 3
- MevrometostatPfizer · Phase 3
Coming up3
- 31 Oct 2028Phase 1 trial completes · ClinicalTrials.gov
- 31 May 2029Phase 1 trial completes · ClinicalTrials.gov
- 31 May 2032Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 31 May 2032 | A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer | |
| Phase 1Recruiting | 31 Oct 2028 | A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer | |
| Phase 1Recruiting | 31 May 2029 | A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026